Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jul 30;21(3):330-6.
doi: 10.5056/jnm15094.

Prokinetics in the Management of Functional Gastrointestinal Disorders

Affiliations

Prokinetics in the Management of Functional Gastrointestinal Disorders

Eamonn M M Quigley. J Neurogastroenterol Motil. .

Abstract

A variety of common and some not common gastrointestinal syndromes are thought to be based on impaired gut motility. For some, the role of motility is well defined, for others and the functional gastrointestinal disorders, in particular, the role of hy-po- or dysmotility remains unclear. Over the years pharmacological and physiological laboratories have developed drugs which stimulate gut motility; many have been evaluated in motility and functional disorders with what can best be described as mixed results. Lack of receptor specificity and resultant expected and unexpected adverse events have led to the demise of some of these agents. Newer, more selective agents offer promise but the heterogeneity of the clinical disorders they target continues to pose a formidable challenge to drug development in this area.

Keywords: Constipation; Dyspepsia; Gastroparesis; Intestinal pseudo-obstruction; Irritable bowel syndrome.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Camilleri M. Pharmacological agents currently in clinical trials for disorders in neurogastroenterology. J Clin Invest. 2013;123:4111–4120. doi: 10.1172/JCI70837. - DOI - PMC - PubMed
    1. Quigley EM. The clinical pharmacology of motility disorders: the perils (and pearls) of prokinesia. Gastroenterology. 1994;106:1112–1114. - PubMed
    1. Quigley EM. The “Con” case. The Rome process and functional gastrointestinal disorders: the barbarians are at the gate! Neurogastroenterol Motil. 2007;19:793–797. doi: 10.1111/j.1365-2982.2007.01000.x. - DOI - PubMed
    1. Quigley EM. Cisapride. What can we learn from the rise and fall of a prokinetic? J Dig Dis. 2011;12:147–156. doi: 10.1111/j.1751-2980.2011.00491.x. - DOI - PubMed
    1. Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5HT4 agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012;35:745–767. doi: 10.1111/j.1365-2036.2012.05011.x. - DOI - PMC - PubMed